Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Patients must have \>= 8 lymph nodes evaluated and reported

Patients must not have presented with clinical complete obstruction or perforation of the bowel

Patients must not have had any systemic or radiation therapy initiated for this malignancy

Patients must not have a previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions:

* Non-melanoma skin cancer, in situ cervical cancer, or breast cancer in situ

* Prior malignancy completely excised or removed and patient has been continuously disease free for \> 5 years

* Patients with completely excised or removed breast cancer and disease free \> 5 years, regardless of the continuation of hormonal therapy

* Patients with previous radiation therapy (RT) to the pelvic region will be ineligible

Patients must be ≥ 18 years old

Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

STEP 2: RANDOMIZATION (HIGH RISK PATIENTS - ARMS A AND B ONLY)

Within 2 weeks prior to randomization, postoperative absolute granulocyte count (AGC) must be \>= 1500/mm\^3 (or \< 1500/mm\^3, if in the opinion of the investigator, this represents an ethnic or racial variation of normal)

Within 2 weeks prior to randomization, the postoperative platelet count must be \>= 100,000/mm\^3

Within 2 weeks prior to randomization, there must be postoperative evidence of adequate hepatic function; bilirubin must be =\< upper limit of normal (ULN) unless the patient has a chronic grade 1 bilirubin elevation due to Gilbert's disease or similar syndrome due to slow conjugation of bilirubin

Within 2 weeks prior to randomization, there must be postoperative evidence of adequate hepatic function; alkaline phosphatase must be \< 2.5 x ULN

Within 2 weeks prior to randomization, there must be postoperative evidence of adequate hepatic function; aspartate transaminase (AST) must be \< 1.5 x ULN

Within 2 weeks prior to randomization, there must be postoperative evidence of adequate renal function; serum creatinine =\< 1.5 x ULN

Within 2 weeks prior to randomization, there must be postoperative evidence of adequate renal function; urine protein/creatinine (UPC) ratio of \< 1.0; patients with a UPC ratio \>= 1.0 must undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate \< 1 gm of protein in order to participate

Patients with a history of hypertension must measure \< 150/90 mmHg and be on a stable regimen of anti-hypertensive therapy

Patients must not have a serious or non-healing wound, skin ulcers or bone fracture

Patients must not have had invasive procedures, defined as follows:

* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization

* Core biopsy or other minor procedure, excluding placement of a vascular access device, within 7 days prior to randomization

* Or anticipate the need for major surgical procedure(s) during the course of the study

Patients must begin adjuvant treatment no less than 28 days and no more than 60 days from surgery

Eligible patients of reproductive potential (both sexes) must agree to use an accepted and effective method of contraceptive during study therapy and for at least 3 months after the completion of bevacizumab; women must not be pregnant or breast-feeding because the study drugs administered may cause harm to an unborn fetus or breastfeeding child; all females of childbearing potential must have a serum pregnancy test to rule out pregnancy within 2 weeks prior to step 2 randomization

* The subject must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on a stable dose of low molecular weight heparin

* The subject must not have active bleeding or a pathological condition that is associated with a high risk of bleeding

* New York Heart Association (NYHA) class III or IV congestive heart failure

* Current symptomatic arrhythmia

* Any non-malignant systemic disease

* Arterial thromboembolic events

* Unstable angina

* Myocardial infarction

Patients must not have a known allergy to platinum compounds

STEP 2: REGISTRATION (LOW-RISK PATIENTS - ARM C)

Patients determined to be low risk are eligible

What this study is about